It is unlikely that the diagnostic utility of BNP testing would be impaired in patients with acute dyspnea who have not been receiving sacubitril/valsartan, but using BNP levels for the guidance of treatment in patients with CHF receiving sacubitril/valsartan may not be feasible. The gene discussed is NPPB; the disease is congestive heart failure.